Slobodan Jared, Gunn Dylan, Thompson Jason, Guggenheimer Kurtis, Brown Keddie, Homenuke Mark, Belak Roy, Banerjee Diponkar, Broemeling David, Marziali Andre
Applied Biophysics Laboratory, The University of British Columbia, and James Hogg iCapture Centre, St. Paul's Hospital, Vancouver, BC, V6T 1Z1, Canada.
Int J Oncol. 2007 Apr;30(4):857-63.
In the field of molecular analysis of cancer, there exists a need for a clinical device that can automate protocols for immunohistochemical and in situ hybridization diagnostic staining on tissue microarrays. The tissue microarray antibody spotter (TMAS) has been developed to provide fundamental improvements over current histological staining techniques by enabling precision application of reagents to individual biopsies within a tissue microarray. This allows for multiplexed reactions on a single slide and promises to significantly reduce costs associated with immunohistochemistry and in situ hybridization based assays. Additionally, because TMAS allows for testing of different biomarkers on each element of a tissue array, a complete cancer profile can be obtained from a single TMA slide. Ultimately this may lead to cost-effective, faster and more accurate diagnosis of the patient.
在癌症分子分析领域,需要一种临床设备,能够自动执行组织微阵列上免疫组织化学和原位杂交诊断染色的协议。组织微阵列抗体点样仪(TMAS)已被开发出来,通过能够将试剂精确应用于组织微阵列内的单个活检样本,对当前的组织学染色技术进行了根本性改进。这允许在一张载玻片上进行多重反应,并有望显著降低与基于免疫组织化学和原位杂交的检测相关的成本。此外,由于TMAS允许在组织阵列的每个元素上测试不同的生物标志物,因此可以从一张TMA载玻片上获得完整的癌症概况。最终,这可能会实现对患者具有成本效益、更快且更准确的诊断。